PE Tech Report


Like this article?

Sign up to our free newsletter

Third Rock Ventures appoints Steven Paul as venture partner

Third Rock Ventures, a venture capital firm focused on launching life sciences companies, has appointed Steven M. Paul as venture partner.

Paul is the former president of the Lilly Research Laboratories of Eli Lilly and now leads the Helen & Robert Appel Institute for Alzheimer’s Research at Weill Cornell Medical College.

As a venture partner, Paul will serve as a senior adviser to the firm and participate in the ideation and development of potential new companies.

"Steve brings invaluable experience to our team as we expand our company building efforts into new therapeutic areas, and we are delighted to welcome him to the Third Rock team," says Kevin Starr, partner, Third Rock Ventures. "In particular, Steve’s distinguished career in neuroscience – especially in CNS drug discovery and development – brings depth to the firm in this area, and we look forward to working with him to create and launch new life sciences companies."

Prior to his appointment at Weill Cornell, Paul spent 17-years at Eli Lilly, during which time he held several key leadership roles, including vice president of neuroscience (CNS) research, group vice president of discovery research (all therapeutic areas). Most recently, he served as president of the Lilly Research Laboratories, where he was responsible for the company’s overall research and development efforts.

Prior to Lilly, Paul served as scientific director of the National Institute of Mental Health. He has also served as medical director in the Commissioned Corps of the US Public Health Service.

"I am excited to be a part of the exceptional team at Third Rock Ventures," says Paul. "I look forward to collaborating with the firm and its expansive network of industry, academic and entrepreneurial partners to build and launch promising companies that will discover and develop innovative new therapies and technologies that will positively impact the lives of patients."

Like this article? Sign up to our free newsletter